Find an MSK Doctor or Cancer Specialist
Francesco Maura

Francesco Maura, MD

Hematologist

Patient Reviews

Areas of Expertise

Conditions I Treat

  • Multiple myeloma

My Specialties

  • Hematology
View all
Dr. Maura's Office Information
Languages: English
Back to top
English
Share

Get to Know Me

I am a hematologist who specializes in treating people with multiple myeloma and other plasma cell disorders. This includes monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma, which are both conditions that can turn into multiple myeloma.

I primarily see patients with multiple myeloma. I also see people in whom the myeloma has returned, as well as those for whom the cancer does not respond to standard treatments. For these patients, we consider salvage therapies and novel immunotherapies, a type of cancer treatment that uses the patient’s immune system to fight cancer.

At Memorial Sloan Kettering Cancer Center (MSK), our myeloma team provides highly specialized and innovative care for patients with multiple myeloma. Patients have access to the latest treatments as well as a vast portfolio of novel therapies.

Read more

Providing care is built on empathy and communication. I make sure patients understand their diagnosis and treatment path and answer their questions clearly. Beyond the treatment plan, my top priority is to establish a strong, communicative relationship with each patient, making sure they feel confident in their care.

I dedicate more than half of my time to research in my lab, where we analyze single-cell and bulk whole genome and RNA sequencing data from B-cell tumors, including multiple myeloma. My mission is to execute research that informs and helps advance clinical practices in cancer care.

Over the past few years, my lab has focused on modeling and integrating clinical and genomic data to better understand how multiple myeloma and other blood disorders such as lymphomas myeloid neoplasms, originate and develop. My goal is to develop genomics-based strategies to improve patient outcomes, prevent organ damage, and minimize side effects of treatments.

Outside of work, I enjoy spending time with my three boys.

What I Do at MSK

A hematologist (HEE-muh-TAH-loh-jist) is a doctor with special training in blood disorders.

  • Assistant Member
Areas of Expertise

Conditions I Treat

  • Multiple myeloma

My Specialties

  • Hematology
Education & Honors

Education

  • MD, University of Milan, Italy

Residencies

  • Hematology, University of Milan, Italy

Fellowships

  • Onco-Hematology and Genomics, University of Milan, Italy

Awards and Honors

  • Best Researcher of the Year, Sylvester Comprehensive Cancer Center, University of Miami Health System(2022)
  • ASH Joanne Levy, MD, Memorial Award for Outstanding Achievement, American Society of Hematology (2021)
  • OncLive Innovation Challenge Silver Award, OncLive (2019)
  • International Myeloma Workshop Young Investigator Award, International Myeloma Society (2019)
  • Societa’ Italiana Ematologia Abstract Achievement Award, American Society of Hematology (2018)

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Contact and Location

Dr. Maura sees patients at one location.

Office Phone
Location
New York, NY
Memorial Sloan Kettering Cancer Center
1275 York Avenue New York NY 10065
Get Directions
Map MarkerA msk map marker icon
Leaflet © OpenStreetMap contributors; © CARTO.

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Myeloma Service doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Maura F*, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, Durante M, Diamond B, Papadimitriou M, Davies F, Boyle EM, Walker B, Hultcrantz M, Silva A, Hampton O, Teer JK, Siegel EM, Bolli N, Jackson GH, Kaiser M, Pawlyn C, Cook G, Kazandjian D, Stein C, Chesi M, Bergsagel L, Mai EK, Goldschmidt H, Weisel KC, Fenk R, Raab MS, Van Rhee F, Usmani S, Shain KH, Weinhold N, Morgan G, Landgren O.J. Genomic Classification and Individualized Prognosis in Multiple Myeloma. Clin Oncol. 2024 Jan 9:JCO2301277. doi: 10.1200/JCO.23.01277. PMID: 38194610.

Maura F*, Boyle EM, Coffey D, Maclachlan K, Gagler D, Diamond B, Ghamlouch H, Blaney P, Ziccheddu B, Cirrincione A, Chojnacka M, Wang Y, Siegel A, Hoffman JE, Kazandjian D, Hassoun H, Guzman E, Mailankody S, Shah UA, Tan C, Hultcrantz M, Scordo M, Shah GL, Landau H, Chung DJ, Giralt S, Zhang Y, Arbini A, Gao Q, Roshal M, Dogan A, Lesokhin AM, Davies FE, Usmani SZ, Korde N, Morgan GJ, Landgren O. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens. Nat Cancer. 2023 Dec;4(12):1660-1674. doi: 10.1038/s43018-023-00657-1. Epub 2023 Nov 9.PMID: 37945755.

Cirrincione AM, Poos AM, Ziccheddu B, Kaddoura M, Bärtsch MA, Maclachlan K, Chojnacka M, Diamond B, John L, Reichert P, Huhn S, Blaney P, Gagler D, Rippe K, Zhang Y, Dogan A, Lesokhin AM, Davies F, Goldschmidt H, Fenk R, Weisel KC, Mai EK, Korde N, Morgan GJ, Usmani S, Landgren O, Raab MS, Weinhold N, Maura F*. The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma. Blood. 2024;144(7):771-783. doi: 10.1182/blood.2024024299.PMID: 38728430.

Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, Chojnacka M, Cirrincione A, Durante M, Tilmont R, Barakat E, Poorebrahim M, Sinha S, McIntyre J, M Y Chan A, Wilson H, Kyman S, Krishnan A, Landgren O, Walter W, Meggendorfer M, Haferlach C, Haferlach T, Einsele H, Kortüm MK, Knop S, Alberge JB, Rosenwald A, Keats JJ, Rasche L, Maura F*, Neri P, Bahlis NJ. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023 Sep;29(9):2295-2306. doi: 10.1038/s41591-023-02491-5. Epub 2023 Aug 31.PMID: 37653344.

Diamond B, Ziccheddu B, Maclachlan K, Taylor J, Boyle E, Ossa JA, Jahn J, Affer M, Totiger TM, Coffey D, Chandhok N, Watts J, Cimmino L, Lu SX, Bolli N, Bolton K, Landau H, Park JH, Ganesh K, McPherson A, Sekeres MA, Lesokhin A, Chung DJ, Zhang Y, Ho C, Roshal M, Tyner J, Nimer S, Papaemmanuil E, Usmani S, Morgan G, Landgren O, Maura F*. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures. Blood. 2023 May 11;141(19):2359-2371. doi: 10.1182/blood.2022018244.PMID: 36626250.  

Publications on PubMed

Visit PubMed for a full listing of Dr. Maura’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed